SecBot SecBot

CLDX drug pipeline

$28.83
+1.1% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
2
1 bullish · 1 neutral
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhasePhase 3 (CSU); Phase 3 (ColdU/SD); Phase 2 (Atopic Dermatitis)
Time to marketBLA submission planned for 2027, followed by a standard 12-month FDA review cycle. If approved, potential launch in late 2028 or early 2029 for CSU.

barzolvolimab Updated Nov 7

What to watch

The Phase 3 CSU binary is behind the stock (positive Sept 2026). The next major catalyst is the BLA submission planned for 2027, which would trigger a ~12-month FDA review cycle. Watch for the BLA filing announcement and any Phase 2 atopic dermatitis data readout, which could provide additional pipeline optionality. The stock trades at ~$30 with a mean analyst target of $63, reflecting the wide gap between current price and potential approval value.

Bull case
  • Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials met primary and all key secondary endpoints at 12 weeks with both dosing regimens (150mg Q4W and 300mg Q8W), described by management as 'best-in-disease' results.
  • Barzolvolimab's novel mechanism (KIT receptor antagonist depleting mast cells) works independently of IgE levels, potentially addressing patients who fail or are not eligible for Xolair.
  • Long-term data showed durable off-treatment responses: up to 64% of patients maintained angioedema improvement 7 months after stopping treatment (Week 76).
Bear case
  • Phase 2 prurigo nodularis trial failed to meet its primary endpoint in July 2026, and the program was discontinued, highlighting clinical risk in indication expansion.
  • Phase 2 eosinophilic esophagitis program was dropped in August 2025 despite meeting its primary endpoint, suggesting the risk/benefit profile may limit the addressable market.
  • The stock fell over 20% on Phase 3 CSU topline day despite positive results, indicating the market may have priced in efficacy or had safety concerns (neutropenia, mast cell depletion).
● neutral
Impact
PhasePhase 1/1b
Time to marketAt least 4-6 years away, assuming successful completion of Phase 1b, Phase 2, and Phase 3 trials plus regulatory review. The drug is still in very early clinical development.

CDX-622 Updated Nov 7

What to watch

CDX-622 has no scheduled binary catalyst in the next 12 months. The next meaningful event would be Phase 1b proof-of-mechanism data in asthma, but no date has been disclosed. For Celldex, the far larger catalyst is the barzolvolimab BLA submission planned for 2027 and any Phase 2 atopic dermatitis data expected in late 2026. CDX-622 is pipeline optionality, not a near-term value driver.

Bull case
  • Positive Phase 1 data showed rapid, dose-dependent reductions in serum tryptase (indicating tissue mast cell depletion) with no dose-limiting toxicities or serious adverse events, validating a novel mechanism.
  • The bispecific approach targeting both SCF and TSLP could differentiate CDX-622 from other mast cell-targeting therapies and from barzolvolimab, expanding Celldex's platform into additional allergic indications.
  • Celldex has a strong balance sheet ($650.3M cash as of Q3 2026) with runway through 2028, providing ample funding to advance CDX-622 through early-stage development without near-term financing risk.
Bear case
  • CDX-622 is in very early clinical development (Phase 1/1b) with no efficacy data in patients yet; the Phase 1 data only showed biomarker changes (tryptase reduction), not clinical outcomes.
  • No hard dated catalyst exists for CDX-622 in the next 12 months, making it a low-impact near-term driver for CLDX stock.
  • Celldex's primary value driver is barzolvolimab; CDX-622 is a small pipeline extension asset that will not materially move the stock until later-stage data emerges.

Other drugs in filings and trials

no drug report yet
  • FLT3 Ligand Therapy (CDX-301) 1 trial

Clinical trials

4 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
barzolvolimabA Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Phase 3Active not recruiting976Oct 2026
barzolvolimabA Study of Barzolvolimab in Patients With Prurigo NodularisPhase 2Active not recruiting140Jun 2026
barzolvolimabA Study of CDX-0159 in Patients With Eosinophilic EsophagitisPhase 2Completed86Jun 4, 2025
FLT3 Ligand Therapy (CDX-301)FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung CancerPhase 2Completed · results33Oct 5, 2022